H3K27M-mutated diffuse midline gliomas (DMGs) are lethal cancers of the central nervous system (CNS). They affect mainly children and young adults, and are a leading cause of childhood-cancer ...

After injection, the CAR-T cells got to work, multiplying and seeking out the target B cells, including the pathogenic ones underlying the autoimmune conditions. This persisted for a few weeks ...

View Full Profile. Learn about our Editorial Policies. Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment ...

Chimeric antigen receptor T cells, better known as CAR T cells, are powerful immunotherapy agents derived from a cancer patient’s existing immune cells and engineered to fight their specific tumors.

The CAR-T cells developed by Hutter's team have an extra feature aimed at altering the microenvironment. The researchers also ...

Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments.

French cell therapy company Celyad is also working in the area, its lead candidate CYAD-01 is an autologous CAR-T NKG2D therapy for use in haematological and solid cancers.

Slovakia’s National Cancer Institute (NOÚ) is offering new hope to patients with otherwise incurable diagnoses, with the launch of innovative CAR T-cell therapy for lymphoma and leukaemia ...